Voriconazole: Difference between revisions
(Replace manual dosing with dynamic SMW tables (Adult + Pediatric)) |
(Restore original dosing content alongside dynamic SMW tables) |
||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*200-400mg PO BID or 4-6mg IV BID | |||
===Indications by Disease=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Voriconazole]] [[Has Population::Adult]] | {{#ask: [[Has DrugName::Voriconazole]] [[Has Population::Adult]] | ||
|?Treats disease=Disease | |?Treats disease=Disease | ||
|?Has Dose=Dose | |?Has Dose=Dose | ||
|?Has Context=Context | |?Has Context=Context | ||
|format=table | |format=table | ||
|limit=50 | |limit=50 | ||
|mainlabel=- | |mainlabel=- | ||
|headers=show | |headers=show | ||
|sort=Treats disease | |sort=Treats disease | ||
}} | }} | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Children >12 yo: same as adult dosing | |||
===Indications by Disease=== | ===Indications by Disease=== | ||
{{#ask: [[Has DrugName::Voriconazole]] [[Has Population::Pediatric]] | {{#ask: [[Has DrugName::Voriconazole]] [[Has Population::Pediatric]] | ||
|?Treats disease=Disease | |?Treats disease=Disease | ||
|?Has Dose=Dose | |?Has Dose=Dose | ||
|?Has Context=Context | |?Has Context=Context | ||
|format=table | |format=table | ||
|limit=50 | |limit=50 | ||
|mainlabel=- | |mainlabel=- | ||
|headers=show | |headers=show | ||
|sort=Treats disease | |sort=Treats disease | ||
}} | }} | ||
Latest revision as of 02:38, 20 March 2026
Administration
- Type: Antifungal (Candida, mycoses, Aspergillosis)
- Dosage Forms:
- Routes of Administration: IV, PO
- Common Trade Names: Vfend
Adult Dosing
- 200-400mg PO BID or 4-6mg IV BID
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Cryptococcosis | 200mg PO q12hrs x 6-12 months | Pulmonary not AIDS associated alt |
Pediatric Dosing
- Children >12 yo: same as adult dosing
Indications by Disease
Special Populations
- Pregnancy Rating: D
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: PO preferred, no adjustement to dose
- Hepatic dosing: mild-moderate impairment- reduce dose. Severe: avoid using
Contraindications
- Allergy to class/drug
- Concomitant use of carbamazepine or CYP3A4 substrates, ritonavir, ergots, barbiturates, rifampin, sirolimus, or St. John's Wort
Adverse Reactions
Serious
- Prolonged QT, dysrhythmias, cardiac arrest
- Erythema multiforme, SJS, TEN
- Malignant melanoma, squamous cell carcinoma
- Hepatotoxicity
- Renal failure
- Toxic encephalopathy
- Pancreatitis
- Optic neuritis
Common
- Peripheral edema
- Rash
- Nausea/vomiting, diarrhea
- Headache
- Visual disturbances
- Hallucinations
- Fever
Pharmacology
- Half-life: Dose dependant, non-linear pharmacokinetics
- Metabolism: CYP2C19, CYP2C9 and CYP3A4
- Excretion: Renal
Mechanism of Action
- Triazole antifungal: inhibits synthesis of fungal cell wall ergosterol